Biochemical effects of irbesartan in experimental diabetic nephropathy.
BACKGROUND
Diabetic nephropathy (DN) is one of the most common causes of end-stage renal failure. The pathogenesis of progressive renal damage is multifactorial and the mechanism by which hyperglycemia causes microangiopathy in diabetic glomeruli is still poorly understood. Because the renin angiotensin system has been reported to be an important contributory factor in the pathophysiology of DN, exogenous administration of angiotensin II receptor antagonist may be beneficial in counteracting some biochemical or functional changes of DN.


OBJECTIVE
The present study was therefore undertaken to evaluate the preventive role of irbesartan in streptozotocin (STZ)-induced DN in rats.


METHODS
STZ-induced DN in rats was assessed biochemically by measuring urine volume, protein and electrolytes as well as blood urea and creatinine clearance.


RESULTS
Marked hyperglycemia, polyuria, proteinuria and uremia along with a reduction in urine electrolytes and creatinine clearance were observed in STZ diabetic rats. Pre-treatment with irbesartan (20 mg/kg, p.o. 5 days prior to STZ and continued for 16 weeks) also significantly altered these parameters towards normal, except blood glucose.


CONCLUSIONS
Pre-treatment with insulin reversed the parameters of DN. The data suggest that irbesartan prevents the development of STZ-induced DN in rats.
Vaishya
Richa
R
Department of Biochemistry, Pt. BD Sharma Postgraduate Institute of Medical Science, Rohtak, Haryana, India.
Singh
J
J
Lal
Harbans
H
Diabetes. 2000 Jan;49(1):87-93
10615954
Indian Heart J. 2000 Jan-Feb;52(1):89-92
10820943
Clin Pharmacol Ther. 1999 Oct;66(4):367-73
10546920
Diabet Med. 1990 Mar-Apr;7(3):252-7
2139398
Kidney Int Suppl. 1996 Dec;57:S132-6
8941934
N Engl J Med. 2001 Sep 20;345(12):870-8
11565519
Drugs. 1986;32 Suppl 2:36-42
3792231
Diabetes Care. 2002 Nov;25(11):1909-13
12401731
Kidney Int Suppl. 1994 Feb;45:S125-31
8158881
Diabetologia. 2001 Nov;44(11):1957-72
11719827
Clin Chem. 1965 Jun;11:624-7
14300078
J Clin Invest. 1999 Oct;104(7):925-35
10510333
J Hypertens. 2003 Jan;21(1):209-16
12544453
Pancreas. 1993 Jul;8(4):459-64
8361966